KR20010080384A - 암 관련 항원 및 이의 동정 방법 - Google Patents

암 관련 항원 및 이의 동정 방법 Download PDF

Info

Publication number
KR20010080384A
KR20010080384A KR1020017005588A KR20017005588A KR20010080384A KR 20010080384 A KR20010080384 A KR 20010080384A KR 1020017005588 A KR1020017005588 A KR 1020017005588A KR 20017005588 A KR20017005588 A KR 20017005588A KR 20010080384 A KR20010080384 A KR 20010080384A
Authority
KR
South Korea
Prior art keywords
tumor
cells
antibody
serum
tumor associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020017005588A
Other languages
English (en)
Korean (ko)
Inventor
달레 안도
주-페이 창
제임스 맥아더
마고 로버츠
조나톤 사이먼스
Original Assignee
스티븐 에이. 서윈. 엠.디.
셀 제네시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 에이. 서윈. 엠.디., 셀 제네시스, 인코포레이티드 filed Critical 스티븐 에이. 서윈. 엠.디.
Publication of KR20010080384A publication Critical patent/KR20010080384A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020017005588A 1998-11-03 1999-11-03 암 관련 항원 및 이의 동정 방법 Withdrawn KR20010080384A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10679598P 1998-11-03 1998-11-03
US60/106,795 1998-11-03
PCT/US1999/025936 WO2000026676A1 (en) 1998-11-03 1999-11-03 Cancer-associated antigens and methods of their identification

Publications (1)

Publication Number Publication Date
KR20010080384A true KR20010080384A (ko) 2001-08-22

Family

ID=22313292

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017005588A Withdrawn KR20010080384A (ko) 1998-11-03 1999-11-03 암 관련 항원 및 이의 동정 방법

Country Status (7)

Country Link
US (2) US7226606B2 (https=)
EP (1) EP1125133A1 (https=)
JP (1) JP2002529707A (https=)
KR (1) KR20010080384A (https=)
AU (1) AU767842B2 (https=)
CA (1) CA2349217C (https=)
WO (1) WO2000026676A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9827103D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
GB0102947D0 (en) * 2001-02-06 2001-03-21 Oxford Biomedica Ltd Method
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer
ATE555212T1 (de) 2007-03-02 2012-05-15 Biosante Pharmaceuticals Inc Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs
WO2008124102A2 (en) * 2007-04-06 2008-10-16 Cell Genesys Inc. Ara-c in combination with a cytokine-secreting cell and use thereof
WO2009095033A1 (en) * 2008-01-31 2009-08-06 Agirx Limited Vaccine compositons
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
KR101942237B1 (ko) 2011-01-04 2019-01-25 신라젠(주) 종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
JP2016530300A (ja) * 2013-09-06 2016-09-29 ニューヨーク・ユニバーシティ シンドビスウイルスベクター及び腫瘍関連抗原を用いる抗腫瘍免疫誘導法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US7176022B2 (en) 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products

Also Published As

Publication number Publication date
AU1340900A (en) 2000-05-22
CA2349217C (en) 2012-07-31
JP2002529707A (ja) 2002-09-10
US7226606B2 (en) 2007-06-05
AU767842B2 (en) 2003-11-27
US20060078544A1 (en) 2006-04-13
US7645587B2 (en) 2010-01-12
US20070212739A1 (en) 2007-09-13
EP1125133A1 (en) 2001-08-22
WO2000026676A1 (en) 2000-05-11
CA2349217A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
US7645587B2 (en) Cancer-associated antigens and methods of their identification and use
JP5291641B2 (ja) 癌抗原及びその利用
US20060275287A1 (en) Scroll compressor
JP2007518399A (ja) 肺癌を診断および治療する組成物並びに方法
HK1202299A1 (en) Novel cancer-associated antigen
US7217421B1 (en) Cancer-associated antigens and methods of their identification and use
Wang et al. The spermatozoa protein, SLLP1, is a novel cancer–testis antigen in hematologic malignancies
Okada et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo
AU2008296927C1 (en) Methods for diagnosing and treating cancers
US7220891B2 (en) Feline bronchioloalveolar lung carcinoma xenograft and cell line
CN114645091B (zh) Rgs1抑制剂在制备乳腺癌肿瘤浸润性淋巴细胞治疗药物中的用途
CA2643737C (en) Cancer vaccine
Zuber et al. Heterogeneity of Melanoma Antigen 1 (MAGE-1) Gene and Protein Expression in Malignant Melanoma
EP1705487A2 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20060194204A1 (en) Gene expressed in prostate cancer, methods and use thereof
Scott Recombinant NY-ESO-1 Protein With ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses In Humans
US20050053988A1 (en) Gene expressed in breast cancer and methods of use
Bunt Immune Suppression and inflammation in the Progression of Breast Cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000